Thursday June 23rd
|
VENUE: Pieterskerk, Kloksteeg 16, Leiden
|
08:00 - end
|
Registration Desk Available
|
| Session III: |
Drug delivery to the brain from a clinical perspective [sponsored by Pfizer] |
| |
Chairs: Tali Siegal (Hadassah Hebrew University of Medical Centre, IL) & |
| |
Pieter Gaillard (to-BBB technologies BV, NL) |
| 08:30 - 09:00 |
Tali Siegal (Hadassah Hebrew University Medical Centre, IL) |
| |
Crossing the barrier and conquest brain tumors: what are down-to-earth expectations? |
| 09:00 - 09:20 |
David Gray (Pfizer Inc, USA) |
| |
Attempts to coax reluctant molecules into the brain parenchyma |
| 09:20 - 09:40 |
William Banks (University of Washington, USA) |
| |
Use of endogenous characteristics of the blood-brain barrier to deliver proteins and |
| |
antisense molecules |
| 09:40 - 10:00 |
Ryan Watts (Neurodegeneration Labs, Genentech Inc, USA) |
| |
Getting antibodies across the blood-brain barrier to target CNS disease |
| |
|
| 10:00 - 10:30 |
Break |
| |
|
| 10:30 - 10:45 |
Nadia Caram-Salas (Institue for Biological Sciences, CAN) |
| |
Brain delviery of analgesic peptides using the blood-brain barrier-transmigrating single domain antibody, FC5 |
| 10:45 - 11:00 |
Pieter Gaillard (to-BBB technologies BV, NL) |
| |
Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain metastases from breast cancer |
| 11:00 - 11:15 |
Ralf Rempe (University of Muenster, DE) |
| |
Transport of Poly(n-butylcyano-acrylate) (PBCA) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity |
| 11:15 - 11:30 |
Reinhard Gabathuler (biOasis Technologies Inc, CAN) |
| |
Development of a new Peptide Vector (p97) for Delivery of Therapeutic Compaounds across the BBB to treat CNS diseases |
| 11:30 - 11:45 |
Ulrich Bickel (Texas Tech University Health Sciences Center, USA) |
| |
Transcytosis of antibodies to MHC Class I at the blood-brain barrier |
| 11:45 - 12:00 |
Adrien Roux (Merck-Serono, CH) |
| |
Development of an antibody-based delivery vehicle for delivering therapeutic molecules into the CNS |
| |
|
| 12:00 - 14:30 |
Lunch and posters |
| |
Poster session II (presenters at posters at 12:30) |
| |
|
Session IV:
|
Inflammation at the blood-brain barrier |
| |
Chairs: Alexandre Prat (CHUM Research Centre, Notre-Dame Hospital, CAN) & |
| |
Elga de Vries (VU University Medical Center, NL)
|
| 14:30 - 15:00 |
Alexandre Prat (CHUM Research Centre, Notre-Dame Hospital, CAN) |
| |
[sponsored by Dutch MS Foundation] |
| |
Brain morphogens and regulation of blood-brain barrier function |
15:00 - 15:20
|
Frauke Zipp (Johannes Gutenberg University Mainz, DE)
|
| |
In vivo imaging of T cells in chronic neuroinflammation
|
15:20 - 15:40
|
Elga de Vries (VU University Medical Center, NL)
|
| |
Inflammation at the blood-brain barrier
|
15:40 - 16:00
|
Ignacio Romero (The Open University, UK)
|
| |
The role of microRNAs in inflammation at the blood-brain barrier
|
| |
|
16:00 - 16:30
|
Break |
| |
|
16:30 - 16:45
|
Arsalan S. Haqqani (Institute for Biological Sciences, CAN) |
| |
Reconstructing in silivo Intercellular Networks between hCMEC/D3 and Th17 cells to identify Potential Therapeutic Targets of CNS Inflammation |
| 16:45 - 17:00 |
Helen Stolp (University of Oxford, UK) |
| |
Vascular gene profile during cerebral inflammatory injury |
| 17:00 - 17:15 |
Daniela Virgintino (University of Bari School of Medicine, IT) |
| |
BBB damage and OPCs proliferation in cerebral cortex: Are they related events during the plastic brain response to demyelination occurring in EAE? |
| 17:15 - 17:30 |
Monique Stins (Johns Hopkins, USA) |
| |
Plasmodium falciparum induces a highly proinflammatory environment at the blood-brain barrier: implications for neurological dysfunction |
| 17:30 - 17:45 |
Chantal Appeldoorn (to-BBB technologies BV, NL) |
| |
Enhanced brain delivery of liposomal methylprednisolone is beneficial for the treatment of neuroinflammation in EAE |
| 17:45 - 18:00) |
Daniel Anthony (University of Oxford, UK |
| |
Endogenous micro particles initiate the acute phase response to brain injury |
